CN116196385A - Traditional Chinese medicine composition for treating fatty liver and/or liver fibrosis as well as preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for treating fatty liver and/or liver fibrosis as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN116196385A CN116196385A CN202310072396.XA CN202310072396A CN116196385A CN 116196385 A CN116196385 A CN 116196385A CN 202310072396 A CN202310072396 A CN 202310072396A CN 116196385 A CN116196385 A CN 116196385A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- medicine composition
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 49
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 49
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 47
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 47
- 208000019425 cirrhosis of liver Diseases 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 13
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 13
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 13
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 13
- 235000008397 ginger Nutrition 0.000 claims abstract description 13
- 239000008517 radix Trichosanthis Substances 0.000 claims abstract description 13
- 241000132012 Atractylodes Species 0.000 claims abstract description 12
- 241000202726 Bupleurum Species 0.000 claims abstract description 12
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 12
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 12
- 241000237502 Ostreidae Species 0.000 claims abstract description 12
- 244000197580 Poria cocos Species 0.000 claims abstract description 12
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 12
- 235000020636 oyster Nutrition 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 244000273928 Zingiber officinale Species 0.000 claims abstract 4
- 244000236658 Paeonia lactiflora Species 0.000 claims description 11
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims description 11
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 8
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 8
- 241001106477 Paeoniaceae Species 0.000 claims description 8
- 229940010454 licorice Drugs 0.000 claims description 8
- 241000213006 Angelica dahurica Species 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 7
- 244000061520 Angelica archangelica Species 0.000 abstract description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 5
- 235000011477 liquorice Nutrition 0.000 abstract description 5
- 244000170916 Paeonia officinalis Species 0.000 abstract 2
- 210000004185 liver Anatomy 0.000 description 21
- 241000234314 Zingiber Species 0.000 description 9
- 238000002099 shear wave elastography Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 235000001188 Peltandra virginica Nutrition 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 3
- 241000736199 Paeonia Species 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 3
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 206010053649 Vascular rupture Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating fatty liver and/or liver fibrosis, and a preparation method and application thereof. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 6-15 parts of bupleurum, 6-9 parts of cassia twig, 6-9 parts of dried ginger, 9-12 parts of radix trichosanthis, 6-9 parts of radix scutellariae, 9-15 parts of raw oyster, 6-9 parts of raw liquorice, 6-15 parts of angelica, 9-12 parts of white paeony root, 6-9 parts of poria cocos, 9-12 parts of ligusticum wallichii, 6-15 parts of bighead atractylodes rhizome, 6-9 parts of rhizoma alismatis and 9-12 parts of red paeony root. The invention provides a traditional Chinese medicine composition capable of effectively treating fatty liver and/or liver fibrosis based on a traditional Chinese medicine theory. The clinical application example results show that the traditional Chinese medicine composition can effectively treat fatty liver or liver fibrosis, and can also treat fatty liver combined liver fibrosis, and compared with the prior art, the traditional Chinese medicine composition has remarkable effect.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine compositions, and in particular relates to a traditional Chinese medicine composition for treating fatty liver and/or liver fibrosis, and a preparation method and application thereof.
Background
Fatty liver (fatty liver) refers to a disorder caused by excessive accumulation of fat in liver cells due to various reasons, and is a common pathological change of liver, not an independent disease. Fatty liver disease is severely threatening the health of people, becomes the second largest liver disease next to viral hepatitis, and the incidence rate is continuously rising and the onset age is getting younger. The liver tissue of normal human contains a small amount of fat such as triglyceride, phospholipid, glycolipid, cholesterol, etc. in an amount of about 3% to 5% by weight of the liver, and can be called fatty liver if the fat accumulation in the liver is too much, exceeds 5% by weight of the liver or more than 50% of the liver cells are steatosis histologically. The clinical manifestations of the medicine are that the patient is asymptomatic, and the patient is fierce in condition of the patient with serious symptoms. Liver fibrosis is a disorder caused by abnormal proliferation of connective tissue of the liver due to injury of the liver caused by pathogenic factors. When the disease is serious, complications such as portal hypertension, liver cirrhosis, hepatic encephalopathy, vascular rupture, liver failure and the like can occur, and the life cycle of a patient can be seriously influenced.
Current treatment of fatty liver and liver fibrosis: the number of the attacks of fatty liver (alcoholic fatty liver disease and nonalcoholic fatty liver disease) is large, the number of the attacks of liver fibrosis (early liver cirrhosis) is large, at present, no medicament can directly treat fatty liver (a guide for preventing and treating nonalcoholic fatty liver disease (2018 updated edition), chinese medical society liver disease science is divided into fatty liver and alcoholic liver disease science), and at present, only a plurality of Chinese patent medicaments for treating liver fibrosis (a guide for diagnosing and treating liver cirrhosis and Chinese medical society liver disease science is divided into liver fibrosis) are marketed globally, so that no medicament can treat fatty liver and liver fibrosis at present, medicaments capable of treating fatty liver are clinically needed, and medicaments capable of simultaneously treating fatty liver and liver fibrosis are needed.
Disclosure of Invention
The invention aims to: in order to solve the defects of the prior art, the invention provides a traditional Chinese medicine composition for treating fatty liver and/or liver fibrosis, and a preparation method and application thereof.
The technical scheme is as follows: in order to achieve the aim of the invention, the invention adopts the following technical scheme:
a traditional Chinese medicine composition for treating fatty liver and/or liver fibrosis comprises the following raw materials in parts by weight:
6-15 parts of bupleurum, 6-9 parts of cassia twig, 6-9 parts of dried ginger, 9-12 parts of radix trichosanthis, 6-9 parts of radix scutellariae,
9-15 parts of raw oyster, 6-9 parts of raw licorice, 6-15 parts of Chinese angelica, 9-12 parts of white peony root, 6-9 parts of poria cocos,
9-12 parts of ligusticum wallichii, 6-15 parts of bighead atractylodes rhizome, 6-9 parts of rhizoma alismatis and 9-12 parts of red paeony root.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight:
8-12 parts of bupleurum, 7-8 parts of cassia twig, 6-9 parts of dried ginger, 10-11 parts of radix trichosanthis, 7-8 parts of radix scutellariae,
10-12 parts of raw oyster, 6-9 parts of raw licorice, 8-12 parts of Chinese angelica, 10-11 parts of white peony root, 7-8 parts of poria cocos,
9-12 parts of ligusticum wallichii, 8-12 parts of bighead atractylodes rhizome, 7-8 parts of rhizoma alismatis and 10-11 parts of red paeony root.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight:
9 parts of bupleurum, 8 parts of cassia twig, 8 parts of dried ginger, 10 parts of radix trichosanthis, 8 parts of radix scutellariae,
12 parts of raw oyster, 8 parts of raw licorice, 10 parts of Chinese angelica, 12 parts of white peony root, 8 parts of poria cocos,
10 parts of ligusticum wallichii, 10 parts of bighead atractylodes rhizome, 8 parts of rhizoma alismatis and 12 parts of red paeony root.
The preparation method of the traditional Chinese medicine composition comprises the following steps:
mixing the above materials, adding 5-30 times of pure water, decocting, and concentrating.
Preferably, the times of decoction are 1-3 times, and each time is 0.5-2 hours.
Preferably, the extract obtained after decoction and concentration can be prepared into liquid preparations, or can be prepared into extract, granules, capsules or pills with or without adding conventional excipients.
The invention finally provides:
the application of the traditional Chinese medicine composition in preparing the medicine for treating fatty liver.
Or the application of the traditional Chinese medicine composition in preparing medicines for treating hepatic fibrosis.
Or the application of the traditional Chinese medicine composition in preparing medicines for treating fatty liver combined with liver fibrosis.
In the formula of the invention, the monarch drug: bupleuri radix, radix Angelicae sinensis, and Atractylodis rhizoma have effects of dispersing stagnated liver qi, promoting blood circulation, invigorating spleen, and eliminating dampness; ministerial drugs: ramulus Cinnamomi, radix Trichosanthis, radix Scutellariae, concha Ostreae, radix Paeoniae alba, radix Paeoniae Rubra, alismatis rhizoma, and Poria, and has effects of regulating cold and heat, promoting blood circulation, and eliminating dampness; adjuvant drug: the dried ginger and the raw licorice have the effects of warming the middle-jiao, strengthening the spleen and regulating the stomach; the preparation method comprises the following steps: ligusticum wallichii has the effects of promoting blood circulation and activating qi-flowing. The whole formula has the effects of harmonizing liver and spleen, harmonizing spleen and stomach, promoting blood circulation by removing blood stasis, strengthening spleen and eliminating dampness, and the like. Has wide clinical application and can treat fatty liver and/or liver fibrosis diseases.
The beneficial effects are that: the invention provides a traditional Chinese medicine composition capable of effectively treating fatty liver and/or liver fibrosis based on a traditional Chinese medicine theory. The clinical application example results show that the traditional Chinese medicine composition can effectively treat fatty liver or liver fibrosis, and can also treat fatty liver combined liver fibrosis, and compared with the prior art, the traditional Chinese medicine composition has remarkable effect.
Drawings
Fig. 1 is a pre-treatment liver shear wave elastography test report using case 2 in a typical case.
Figure 2 is a report of post-treatment liver shear wave elastography detection using case 2 in a typical case.
Fig. 3 is a pre-treatment liver shear wave elastography test report using case 4 in a typical case.
Fig. 4 is a report of post-treatment liver shear wave elastography detection using case 4 in a typical case.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Example 1
The formula comprises the following components:
9g of bupleurum, 8g of cassia twig, 8g of dried ginger, 10g of radix trichosanthis, 8g of baikal skullcap root,
12g of raw oyster, 8g of raw liquorice, 10g of angelica, 12g of white peony root, 8g of tuckahoe,
ligusticum wallichii 10g, white atractylodes rhizome 10g, oriental waterplantain rhizome 8g, red peony root 12g.
The preparation method comprises the following steps:
mixing the above materials, adding 1000ml of pure water, boiling with strong fire, and decocting with slow fire to 400ml of medicinal liquid. When in use, the composition is taken for 2 times a day, 1 time and 200ml.
Example 2
The formula comprises the following components:
6g of bupleurum, 9g of cassia twig, 6g of dried ginger, 12g of radix trichosanthis, 6g of radix scutellariae,
15g of raw oyster, 6g of raw liquorice, 15g of angelica, 9g of white peony root, 9g of tuckahoe,
ligusticum wallichii 9g, white atractylodes rhizome 15g, oriental waterplantain rhizome 6g, red peony root 12g.
The preparation method comprises the following steps:
mixing the above materials, adding 1000ml of pure water, boiling with strong fire, and decocting with slow fire to 400ml of medicinal liquid. When in use, the composition is taken for 2 times a day, 1 time and 200ml.
Example 3
The formula comprises the following components:
15g of bupleurum, 6g of cassia twig, 9g of dried ginger, 9g of radix trichosanthis, 9g of baikal skullcap root,
9g of raw oyster, 9g of raw liquorice, 6g of angelica, 12g of white peony root, 6g of tuckahoe,
12g of ligusticum wallichii, 6g of bighead atractylodes rhizome, 9g of rhizoma alismatis and 9g of red paeony root.
The preparation method comprises the following steps:
mixing the above materials, adding 1000ml of pure water, boiling with strong fire, and decocting with slow fire to 400ml of medicinal liquid. When in use, the composition is taken for 2 times a day, 1 time and 200ml.
Example 4
The formula comprises the following components:
8g of bupleurum, 8g of cassia twig, 6g of dried ginger, 11g of radix trichosanthis, 7g of radix scutellariae,
12g of raw oyster, 6g of raw licorice, 12g of Chinese angelica, 10g of white peony root, 8g of tuckahoe,
ligusticum wallichii 9g, white atractylodes rhizome 12g, oriental waterplantain rhizome 7g, red peony root 11g.
The preparation method comprises the following steps:
mixing the above materials, adding 1000ml of pure water, boiling with strong fire, and decocting with slow fire to 400ml of medicinal liquid. When in use, the composition is taken for 2 times a day, 1 time and 200ml.
Example 5
The formula comprises the following components:
12g of bupleurum, 7g of cassia twig, 9g of dried ginger, 10g of radix trichosanthis, 8g of radix scutellariae,
10g of raw oyster, 9g of raw liquorice, 8g of angelica, 11g of white peony root, 7g of tuckahoe,
12g of ligusticum wallichii, 8g of bighead atractylodes rhizome, 8g of rhizoma alismatis and 10g of red paeony root.
The preparation method comprises the following steps:
mixing the above materials, adding 1000ml of pure water, boiling with strong fire, and decocting with slow fire to 400ml of medicinal liquid. When in use, the composition is taken for 2 times a day, 1 time and 200ml.
Clinical application example:
1. clinical data
20 patients with fatty liver complicated with liver fibrosis were examined in a third affiliated hospital of naval medical university of third class A, etc. at the period of 2020 month 03 to 2023 month 01.
2. Diagnostic criteria
Fatty liver diagnostic criteria: reference is made to the guidelines for prevention and treatment of non-alcoholic fatty liver disease (2018 updated edition) and the guidelines for diagnosis and treatment of non-alcoholic fatty hepatitis in Chinese medicine
Noninvasive quantitative diagnosis of fatty liver by detection of Controlled Attenuation Parameter (CAP), which can measure liver fat content, mild fatty liver: CAP of 0.62-0.67 db/cm to fat content grade of 51-33%; moderate fatty liver: CAP is more than or equal to 0.67 and less than 0.73db/cm, and the fat content grade is 34-66 percent; severe fatty liver: CAP is more than or equal to 0.73db/cm, and the corresponding fat content grade is more than or equal to 67 percent.
3. Therapeutic method
The medicine obtained in the example 1 of the invention is orally taken for 14 days, 1 dose is taken for 1 time and 200ml is taken every day, and liver shear wave elastography examination is carried out before and after treatment.
4. Efficacy evaluation criteria
Cure (disappearance of fatty liver and liver fibrosis), effective (alleviation of fatty liver and liver fibrosis), ineffective (no change or aggravation of fatty liver and liver fibrosis), total effective rate= (cure number + effective number)/total number of people.
5. Therapeutic results
2 cases are cured, 18 cases are effective, and the total effective rate is 100%.
6. Typical cases
Case 1 was used: the patient is someplace in his or her trunk, male, 42 years old. Fatty liver was found for 5 years, hospital liver shear wave elastography detection report: liver moderate fatty liver; liver fibrosis. The result of the re-examination after taking the recipe for 14 days shows that the fatty liver and the liver fibrosis are both improved.
Case 4 used: the patient is on a certain scale, female, 67 years old. Fatty liver for 6 years, hospital liver shear wave elastography detection report: liver moderate fatty liver; liver fibrosis. The result of the re-examination after taking the recipe for 14 days shows that the fatty liver and the liver fibrosis disappear.
The above examples illustrate only a few embodiments of the invention, which are described in detail and are not to be construed as limiting the scope of the invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention. Accordingly, the scope of protection of the present invention is to be determined by the appended claims.
Claims (9)
1. The traditional Chinese medicine composition for treating fatty liver and/or liver fibrosis is characterized by comprising the following raw materials in parts by weight:
6-15 parts of bupleurum, 6-9 parts of cassia twig, 6-9 parts of dried ginger, 9-12 parts of radix trichosanthis, 6-9 parts of radix scutellariae,
9-15 parts of raw oyster, 6-9 parts of raw licorice, 6-15 parts of Chinese angelica, 9-12 parts of white peony root, 6-9 parts of poria cocos,
9-12 parts of ligusticum wallichii, 6-15 parts of bighead atractylodes rhizome, 6-9 parts of rhizoma alismatis and 9-12 parts of red paeony root.
2. The traditional Chinese medicine composition for treating fatty liver and/or liver fibrosis according to claim 1, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight:
8-12 parts of bupleurum, 7-8 parts of cassia twig, 6-9 parts of dried ginger, 10-11 parts of radix trichosanthis, 7-8 parts of radix scutellariae,
10-12 parts of raw oyster, 6-9 parts of raw licorice, 8-12 parts of Chinese angelica, 10-11 parts of white peony root, 7-8 parts of poria cocos,
9-12 parts of ligusticum wallichii, 8-12 parts of bighead atractylodes rhizome, 7-8 parts of rhizoma alismatis and 10-11 parts of red paeony root.
3. The traditional Chinese medicine composition for treating fatty liver and/or liver fibrosis according to claim 1, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight:
9 parts of bupleurum, 8 parts of cassia twig, 8 parts of dried ginger, 10 parts of radix trichosanthis, 8 parts of radix scutellariae,
12 parts of raw oyster, 8 parts of raw licorice, 10 parts of Chinese angelica, 12 parts of white peony root, 8 parts of poria cocos,
10 parts of ligusticum wallichii, 10 parts of bighead atractylodes rhizome, 8 parts of rhizoma alismatis and 12 parts of red paeony root.
4. A method for preparing the traditional Chinese medicine composition according to any one of claims 1 to 3, comprising the following steps:
mixing the above materials, adding 5-30 times of pure water, decocting, and concentrating.
5. The method for preparing a Chinese medicinal composition according to claim 4, wherein the number of times of decoction is 1-3 times, each time for 0.5-2 hours.
6. The method of preparing a pharmaceutical composition according to claim 4, wherein the extract obtained after the concentration by decoction is formulated into a liquid preparation, or formulated into an extract, granule, capsule or pill with or without conventional excipients.
7. Use of the traditional Chinese medicine composition according to any one of claims 1-3 in the preparation of a medicament for treating fatty liver.
8. Use of a traditional Chinese medicine composition according to any one of claims 1-3 for the preparation of a medicament for the treatment of liver fibrosis.
9. Use of a traditional Chinese medicine composition according to any one of claims 1-3 in the preparation of a medicament for treating fatty liver-associated liver fibrosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310072396.XA CN116196385A (en) | 2023-02-07 | 2023-02-07 | Traditional Chinese medicine composition for treating fatty liver and/or liver fibrosis as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310072396.XA CN116196385A (en) | 2023-02-07 | 2023-02-07 | Traditional Chinese medicine composition for treating fatty liver and/or liver fibrosis as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116196385A true CN116196385A (en) | 2023-06-02 |
Family
ID=86516664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310072396.XA Pending CN116196385A (en) | 2023-02-07 | 2023-02-07 | Traditional Chinese medicine composition for treating fatty liver and/or liver fibrosis as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116196385A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105561139A (en) * | 2014-10-10 | 2016-05-11 | 杨军 | Traditional Chinese medicine formula for treating liver qi stagnation-type fatty liver |
| CN111544498A (en) * | 2020-05-20 | 2020-08-18 | 天津中医药大学 | New application of angelica sinensis and peony powder |
-
2023
- 2023-02-07 CN CN202310072396.XA patent/CN116196385A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105561139A (en) * | 2014-10-10 | 2016-05-11 | 杨军 | Traditional Chinese medicine formula for treating liver qi stagnation-type fatty liver |
| CN111544498A (en) * | 2020-05-20 | 2020-08-18 | 天津中医药大学 | New application of angelica sinensis and peony powder |
Non-Patent Citations (2)
| Title |
|---|
| 冯而标，等: "柴胡桂枝干姜汤合当归芍药散加减治疗肥胖患者高脂血症238例", 广西中医药, vol. 37, no. 03, pages 56 - 57 * |
| 刘丙林，等: "柴胡桂枝干姜汤临证验案3则", 中医研究, no. 07, pages 20 - 21 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6911221B2 (en) | Anti-neoplastic drug | |
| CN111671880B (en) | Traditional Chinese medicine preparation for treating fever caused by coronavirus pneumonia | |
| CN104288412B (en) | A kind of Chinese medicine composition for treating metabolic syndrome | |
| CN103301400A (en) | Traditional Chinese medicinal composition for treating chronic atrophic gastritis and preparation method of traditional Chinese medicinal composition | |
| CN110742990B (en) | Traditional Chinese medicine composition for treating non-alcoholic simple fatty liver, preparation and application | |
| CN1679892A (en) | Oral liquid for treating cancer and preparation thereof | |
| CN104352793A (en) | Traditional Chinese medicine preparation for treating gastrointestinal bleeding and preparation method thereof | |
| CN101658657A (en) | Drug for treating chronic cholecystitis | |
| CN105311492A (en) | Medicine for treating coronary atherosclerotic heart disease | |
| CN115414458A (en) | A Chinese medicinal composition for treating hepatitis B, and its preparation method | |
| CN112336802B (en) | Traditional Chinese medicine composition for improving glycolipidosis metabolism of diabetes and application thereof | |
| CN101987135B (en) | Medicine for treating tetanus and preparation method thereof | |
| CN116196385A (en) | Traditional Chinese medicine composition for treating fatty liver and/or liver fibrosis as well as preparation method and application thereof | |
| CN108619427B (en) | Pain-relieving and acid-reducing herb tea for preventing and treating gouty arthritis | |
| CN112220846A (en) | Traditional Chinese medicine composition for treating children's chronic cough and application thereof | |
| CN104998158A (en) | Pharmaceutical composition for treating liver cirrhosis and application thereof | |
| CN105194352B (en) | A kind of Chinese medicine composition and preparation method thereof improving learning and memory | |
| CN118286310B (en) | Application of nux Prinsepiae or extract and composition thereof in treating and/or preventing liver injury | |
| TWI825996B (en) | Compositions for treating diseases and/or symptoms caused by the new coronavirus | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN107753914B (en) | Pharmaceutical composition for treating liver cirrhosis and preparation method thereof | |
| CN101637533B (en) | Application of Chinese medicinal composition in preparation of medicament for treating virus myocarditis | |
| CN106581468A (en) | Preparation method of traditional Chinese medicine capable of treating gastric ulcer | |
| CN104940730A (en) | Traditional Chinese medicine composition for treating metabolic syndrome | |
| CN117122661A (en) | Traditional Chinese medicine composition and preparation for treating chronic cholecystitis liver Yu Dan heat syndrome and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |